Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

Can you get an investing edge using Emotional Intelligence?

Carolyn Stern , a certified Emotional Intelligence and Leadership Development Expert, and an award-winning author of The Emotionally Strong Leader joins The Market Online to discuss Emotional Intelligence in Investing and financial decision-making. Emotional intell...

Decoding patient data sets to help clinical trials succeed

How well do you know your clinical patients? What if there was a way to uncover the hidden relationship between patients in clinical trials empowering scientists to make critical decisions. Lyndsay Malchuk from Stockhouse Publishing recently sat down with NetraMark Hold...

Revolutionizing immunotherapies with groundbreaking DPX platform

The following is a transcription of the above video, and The Market Online has edited it for clarity . BioVaxys Technology Corp (CSE:BIOV) is a Canadian-based clinical stage biopharmaceutical company focused on improving patient lives with novel immunotherapies. CE...

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...

Is this stunning 'evidence' that NervGen has the goods?

This could be the signal that tiny NervGen Pharma Corp. (TSX-V:NGEN; OTCQX:NGENF) is destined to be one of the top performing biotech startup stocks this year. It came in a seemingly innocuous podcast interview about the company’s ongoing Phase 1b/2...

Pharmaceutical company treats bladder cancer with new tech

The following is a transcription of the above video, and The Market Herald Canada has edited it for clarity . Theralase Technologies Inc. (TSXV:TLT) , a clinical-stage pharmaceutical company, is currently developing an innovative, research-backed technology for the ...

ExoTherapy offers hope for treating acute spinal cord injuries

Suffering from traumatic injuries can leave a person with long-term damages and/or side effects that are hard to navigate long after the initial incident has passed. Our next company is a publicly traded bio-pharmaceutical company, working on the development of its ...

NetraMark Holdings, bridging an important pharmaceutical industry gap

NetraMark Holdings is a tech company, looking to identify and fill current gaps in the pharmaceutical industry. The Toronto-based company offers its proprietary algorithms to change the way in which Artificial Intelligence is used in the field, uncovering insights fro...

POET Technologies: Making the Internet Faster

Headquartered in Toronto with operations in the US, Singapore and China – Poet Technologies has created the first-ever wafer-level integration of electronics and photonics into a single device called the POET Optical Interposer. The Interposer achieves electronics and pho...
1 2 3 4 5 6 7 8 9